Alcon & Origenis intensify relationship

Article

Alcon & Origenis intensify relationship

German firm Origenis has extended its research alliance with Alcon Research, to develop small molecule drugs against important ophthalmic targets, for two years.

Origenis' MOREsystem enables the directed target and indication optimized exploitation of billions of novel compounds through a proprietary multiparametric optimization process. Origenis will apply this platform to deliver preclinical candidates with indication optimized profiles for certain Alcon targets. Alcon, in turn, will bring its applied biology expertise, screening capabilities and development proficiency to the alliance.

Under the terms of the agreement, Alcon will retain the rights to any ophthalmic or nasal applications developed and will make research payments to Origenis through a series of development milestones and royalties on sales. Origenis will retain certain rights to all other uses of drug candidates discovered during the alliance.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.